Jilin Zixin Pharma to Pay $42 Million for Majority Stake in US Genome Mapping Company

Jilin Zixin Pharma will invest $42 million in Nabsys 2.0, a US company that has developed a high-definition genome mapping technology. After the transaction, Zixin will own 67% of Nabsys. Nabsys, which claims to be an electronic mapping pioneer, uses proprietary chip-based nanodetectors for single-molecule DNA mapping. It expects its technology will allow structural variation analysis, genome mapping, and in the future, DNA sequencing. The fundraising values Nabsys at $63 million. More details.... Stock Symbol: (SHZ: 2118) Share this with colleagues: // //